<DOC>
	<DOCNO>NCT01850524</DOCNO>
	<brief_summary>This phase 3 , randomize , double-blind , multicenter study evaluate safety efficacy IXAZOMIB versus placebo add lenalidomide dexamethasone ( LenDex ) patient Newly Diagnosed Multiple Myeloma ( NDMM ) eligible stem cell transplant .</brief_summary>
	<brief_title>IXAZOMIB Plus Lenalidomide Dexamethasone Versus Placebo Plus Lenalidomide Dexamethasone Adult Patients With Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Male female patient 18 year old diagnose Multiple Myeloma accord standard criterion receive prior treatment Patients lenalidomide dexamethasone treatment appropriate eligible highdose therapy follow stemcell transplantation ( HDTSCT ) 1 follow reason : 1. patient 65 year age old 2. patient less 65 year age significant comorbid condition ( ) , opinion investigator , likely negative impact tolerability HDTSCT Measurable disease specify study protocol Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Meet clinical laboratory criterion specify protocol Female patient post menopausal , surgically sterile , agree practice 2 effective method contraception agree practice true abstinence , must also agree ongoing pregnancy test ; must also adhere guideline lenalidomide pregnancy prevention program Male patient agree practice effective barrier contraception agree practice true abstinence AND must adhere guideline lenalidomide pregnancy prevention program Suitable venous access studyrequired blood sampling Must able take concurrent aspirin 70mg 325 mg daily ( enoxaparin aspirin allergic ) Voluntary write consent Patient willing able adhere study visit schedule protocol requirement Prior treatment multiple myeloma either standard care treatment investigational regimen Diagnosed treat another malignancy within 5 year randomization previously diagnose another malignancy evidence residual disease . Patients nonmelanoma skin cancer carcinoma situ type exclude undergone complete resection Inability unwillingness receive antithrombotic therapy Female patient lactate pregnant Major surgery radiotherapy within 14 day randomization Infection require intravenous antibiotic within 14 day first dose study drug Central nervous system involvement Diagnosis Waldenstrom 's macroglobulinemia , POEMS syndrome , plasma cell leukemia , primary amyloidosis , myelodysplastic syndrome , myeloproliferative syndrome Evidence current uncontrolled cardiovascular condition Systemic treatment strong inhibitor CYP1A2 ( fluvoxamine , enoxacin , ciprofloxacin ) , strong inhibitor CYP3A ( clarithromycin , telithromycin , itraconazole , voriconazole , ketoconazole , nefazodone , posaconazole ) strong CYP3A inducer ( rifampin , rifapentine , rifabutin , carbamazepine , phenytoin , phenobarbital ) , use Ginkgo biloba St. John 's wort within 14 day randomization study Active hepatitis B C virus infection , know human immunodeficiency virus ( HIV ) positive Comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribe regimen ( eg , peripheral neuropathy Grade 1 pain Grade 2 high cause ) Serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol Known allergy study medication Inability swallow oral medication , inability unwillingness comply drug administration requirement , gastrointestinal ( GI ) procedure could interfere oral absorption tolerance treatment Treatment investigational product within 60 day first dose study drug regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Newly Diagnosed multiple myeloma</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>MLN9708</keyword>
	<keyword>IXAZOMIB</keyword>
	<keyword>Proteasome inhibitor</keyword>
	<keyword>Tourmaline MM2</keyword>
</DOC>